Usage Rights: All content is available for editorial use with attribution to The Ohio State University Wexner Medical Center.
A clinical trial at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is exploring a novel approach to treat mental health struggles in lung cancer patients: psilocybin-assisted therapy.
Key story takeaways include:
- First of its kind: This is the first psychedelic therapy trial specifically designed for lung cancer patients.
- Addressing a critical gap: Nearly 40% of lung cancer patients experience severe depression, anxiety and distress. This therapy aims to heal the mind while standard oncology treats the body.
- Comprehensive care: Conducted in a highly controlled setting, patients receive eight hours of preparation, a single supervised dosing session, and extensive post-treatment integration therapy.
- Promising results: Participants report a renewed sense of purpose, less focus on physical pain and greater peace regarding their mortality.
Ohio State is actively enrolling eligible non-small cell lung cancer patients with moderate to severe depression, aiming to transform the future of cancer care.
